Fortress Biotech, Inc. (NASDAQ:FBIOP) Short Interest Down 50.0% in October

Fortress Biotech, Inc. (NASDAQ:FBIOP) saw a significant decline in short interest in October. As of October 31st, there was short interest totalling 100 shares, a decline of 50.0% from the October 15th total of 200 shares. Based on an average daily volume of 20,400 shares, the days-to-cover ratio is currently 0.0 days.

Fortress Biotech Trading Down 0.4 %

NASDAQ FBIOP traded down $0.02 during trading hours on Wednesday, reaching $5.15. 28,448 shares of the company’s stock traded hands, compared to its average volume of 17,342. Fortress Biotech has a 52-week low of $4.86 and a 52-week high of $18.00. The firm has a 50-day simple moving average of $5.50 and a 200 day simple moving average of $9.77.

Fortress Biotech Company Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.